Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Espen A. Haavardsholm
With
The Research Council of Norway
Smerud Medical Research International AS
Oslo University Hospital
Innovest
Abbott
UCB Nordic A/S
Pfizer
MSD Norway AS
Roche Pharma AG
The Norwegian Rheumatism Association
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or non-pregnant, non-nursing female
\> 18 years of age and \< 75 years of age
Patients classified as having RA (according to new ACR/EULAR criteria)
Disease duration less than 2 years (defined as time from 1st joint swelling)
The treating rheumatologist decides the patient requires treatment with a Disease Modifying Anti-Rheumatic Drug (DMARD)
The patient has taken no prior DMARD
Patients able and willing to give written informed consent and comply with the requirements of the study protocol
You may not be if
Abnormal renal function (serum creatinine \> 142 µmol/L in female and \> 168 µmol/L in male)
Abnormal liver function, active or recent hepatitis, cirrhosis
Major co-morbidities like severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease and/or severe respiratory diseases.
Leukopenia and/or thrombocytopenia
Inadequate birth control conception, pregnancy, and/or breastfeeding
Indications of active tuberculosis
Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible
